• Mashup Score: 1

    I have to say, this new paper is good news on the oncology front. It’s from researchers at Sloan-Kettering and BioNTech (among others) and presents the results of a small trial treating patients with pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC). This is another crack at the “personalized cancer therapy” idea and simultaneously at the “cancer vaccine” idea, and it’s fair…

    Tweet Tweets with this article
    • Nice summary of "effect size" in #mRNAvaccines for #PancreaticCancer in @ScienceMagazine 👇🏽 https://t.co/8y74mxRNEQ But: 50% no response = ❓as non-responders enriched (not ss) in pts with no spleen. Spleen ⬆️ IV #mRNAvaccine response (👉🏽🧵 https://t.co/8ndGZADgDH )

  • Mashup Score: 0

    A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell activity that may correlate with delayed recurrence of disease.

    Tweet Tweets with this article
    • ICYMI - our thread on #mRNAvaccines for #PancreaticCancer in @Nature https://t.co/d1SgGgdVHq 👇🏽 https://t.co/8ndGZADgDH + interesting take below 👇🏽 https://t.co/HMomidxcZd

  • Mashup Score: 2

    Of the 16 patients who were able to complete all phases of the study, eight responded to the vaccine, which taught their immune systems how to recognize and fight off the cancer cells. None of those eight has seen their cancer return.

    Tweet Tweets with this article
    • ICYMI 👇🏽 Nice description of our work on #mRNAvaccines for #PancreaticCancer from @CNN Delves a little into why 50% non-response to vaccines (is it the spleen?) https://t.co/YoEPM5wnA8 Our tweetorial on the research 👇🏽 https://t.co/8ndGZADgDH @drsanjaygupta